Kornimate/medical-research-clean huggingface dataset:
apomorphine effects on pain in parkinson's disease

Conditions: Parkinson Disease

Summary: to study the effects of acute apomorphine vs. placebo administration on different parkinson's disease pain types.

apomorphine is the only anti-parkinsonian agent compatible with levodopa in improving parkinson's disease (pd) motor symptoms. besides, it has positive effects on some of the nonmotor symptoms of the disease, such as urinary disturbances and sleep. apomorphine is usually well tolerated as it produces limited side effects. knowledge about the effects of apomorphine on pain in pd is scarce. evidence on this topic has only been reported in case reports or small studies but represents a potentially important use of the drug. we hypothesize that apomorphine may be a rational, safe, and useful treatment for subjects with pain in pd, including different subtypes. within this framework, the present study will evaluate the effect of acute apomorphine vs. placebo administration on different pd pain types.

Eligibility criteria:
inclusion criteria: * subjects with pd according to the mds clinical diagnostic criteria for parkinson's disease. * participants on antiparkinsonian medication in advanced stages of the disease and experiencing off periods and pain. * apomorphine treatment naïve subjects or not received any within the last six months. * stable pd and pain medications for at least 30 days. * competence to self-report pain severity in the king's parkinson's disease pain scale and a likert visual analogue scale. exclusion criteria: * subjects who are unable to self-report pain severity in the selected scales. patients that may require a translator or are illiterate will be included if they can self-report pain severity. * subjects with a diagnosis of dementia (montreal cognitive assessment \<20). * subject with poorly controlled orthostatic hypotension. * subjects associated with another medical condition, e.g., any cardiovascular, renal or hepatic impairment, hematological or psychiatric diseases. any contraindication to receiving apomorphine injections: * subjects who are hypersensitive to apomorphine or any ingredient in the formulation or component of the container (hydrochloric acid concentrated, sodium bisulfite (e222), and water) * subjects using concomitant drugs of the 5ht3 antagonist class including (e.g., ondansetron, granisetron, palonosetron) * subjects using concomitant antihypertensive medications or vasodilators * subjects with prolonged qt on an electrocardiogram.
diabetic ketoacidosis and its impact on the brain

Conditions: Diabetes Mellitus

Summary: about the study: this research study is being conducted to see if diabetic ketoacidosis has any impact on learning, behavior and development in children with type 1 diabetes mellitus. if there is an impact, is it transient or persistent? sixty to 80 children between the ages of 4 to 17 years with type 1 diabetes mellitus will have neuropsychological testing and a non-sedated mri scan of the head performed. the investigators will compare this to a control group of 30-40 children between the ages of 4 to 17 years without type 1 diabetes mellitus. the children with type 1 diabetes mellitus will not have any changes made to their current diabetes regimen. the children with type 1 diabetes mellitus should continue to check blood glucose values as required by your doctor and bring their meter(s) for downloading to each visit. the children with type 1 diabetes mellitus should also tell your doctor about the frequency of severe low and high blood glucose values.

participant schedule: 1. one visit for 3-4 hours at the stanford medical center to complete neuropsychological testing and to become familiar with the mri scanner. 2. subjects who need to become more familiar with the mri scanning process will view a video tape at home. 3. one visit for 1-2 hours at stanford medical center to have the mri scan of the head completed. 4. subjects between 10 and 17 years of age will also be asked to complete two additional abbreviated neuropsychological tests at one week and one month from enrollment. 5. subjects may have the complete neuropsychological testing and mri scan repeated 15 months from time of enrollment.

Eligibility criteria:
inclusion criteria: to take part in the study, the participant must meet the following inclusion criteria: 1. be between the ages of 4 to 17 years. 2. either has been diagnosed with type 1 diabetes mellitus or does not have type 1 diabetes mellitus exclusion criteria: if the interested participant has a history of head trauma with any loss of consciousness, prematurity (born less than 30 weeks of gestation), significant developmental delay (lack of single word speech or ability to walk independently by 18 months of age), neurologic disease independent of diabetes (eg seizure disorder or medical contraindication to mri procedure (eg metal appliances such as braces).
study evaluating the safety and efficacy of etanercept 50 mg once weekly in subjects with psoriasis

Conditions: Psoriasis

Summary: the primary objective is to assess the efficacy and safety of etanercept 50 mg administered once weekly in subjects with psoriasis over 12 weeks.


Eligibility criteria:
inclusion criteria: -adults greater than or equal to 18 years of age with clinically stable plaque psoriasis involving greater than or equal to 10% of the body surface and a minimum psoriasis area and severity index (pasi) score of 10 at screening. -failure to respond to, or have a contraindication to, or intolerant to at least 1 of the following systemic or phototherapies at an adequate dose of sufficient duration: methotrexate (mtx), acitretin, cyclosporine, ultraviolet a (uva), ultraviolet b (uvb), psoralen and ultraviolet a (puva), fumarate exclusion criteria: -previous treatment with etanercept, antibody to tnf or other tnf inhibitors. -active guttate, erythrodermic, or pustular psoriasis at the time of the screening or baseline.\&#xd;

Keywords: psoriasis
the effectiveness and safety of glofitamab in real-world clinical practice among chinese adult patients with relapsed or refractory diffuse large b-cell lymphoma: a prospective, observational, multicenter study

Conditions: Diffuse Large B Cell Lymphoma (DLBCL)

Summary: the purpose of this study is to evaluate the the efficacy and safety in the real-world settings of glofitamab among chinese r/r dlbcl participants.


Eligibility criteria:
inclusion criteria: * be diagnosed as r/r dlbcl * participants who will be treated with glofitamab (known as being recommended and having the intention to be treated with glofitamab at the time of signing informed consent) or have initiated glofitamab treatment within 6 months prior to enrollment and after the indication approval will be observed in this study. exclusion criteria: * any other reason that, in the investigator's opinion, makes the participant unsuitable to participate in this study.
flavors and e-cigarette effects in adolescent smokers- study 1

Conditions: Nicotine Dependence, Other Tobacco Product

Summary: this study is to examine if inhaled doses of menthol that produce low and high cooling effects change the appeal of e-cigarettes containing low and high doses of nicotine in adolescent smokers. the hypothesis is that the combination of nicotine and menthol, when compared with menthol or nicotine alone, will result in greater increase in liking of an e-cigarette and greater reduction in nicotine withdrawal.


Eligibility criteria:
inclusion criteria: * ages 18-20 years * able to read and write * cigarette smoker * use of e-cigarettes in the past 30 days exclusion criteria: * seeking smoking cessation treatment * current/lifetime criteria for dependence on another psychoactive substance -daily use of alcohol or marijuana or use of any other drugs including cocaine, opiates, stimulants * regular use of psychoactive drugs including anxiolytics, antidepressants and other psychostimulants * current or past history of psychosis or other psychiatric diagnosis such as major depression * any significant current medical condition

Keywords: tobacco electronic cigarettes menthol flavors
evaluation of safety, immune-response and efficacy of gsk biologicals' ebv (epstein barr virus) vaccine (268664).

Conditions: Epstein Barr Virus (EBV) Infection

Summary: to evaluate the safety, immune-response and efficacy of gsk biologicals' ebv vaccine in a population at risk of developing infectious mononucleosis. each subject will receive three doses of vaccine or placebo during the study period.


Eligibility criteria:
inclusion criteria: * healthy adolescent/adult subjects between and including 16 and 25 years of age at the time of screening. * written informed consent obtained from the subject prior to enrolment. * seronegative for ebv antibody. exclusion criteria: * administration of immunoglobulin and/or any blood products within the three months (90 days) preceding the first dose of study vaccine or planned administration during the study period. * use of any investigational or non-registered drug or vaccine other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period. * any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (hiv) infection. * family history of congenital or hereditary immunodeficiency. * major congenital defects or serious chronic illness. * history of any neurologic disorders or seizures, with the exception of a single febrile seizure during childhood. * acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests. * history of intravenous drug abuse within the past 2 years. * known or suspected allergy to any vaccine component.

Keywords: epstein barr virus belgium infectious mononucleosis
feasibility of the braingate2 neural interface system in persons with tetraplegia (bg-tablet-01)

Conditions: Brainstem Stroke; ALS; Tetraplegia; Spinal Cord Injuries; Cervical Spinal Cord Injury

Summary: people with brainstem stroke, advanced amyotrophic lateral sclerosis (als, also known as lou gehrig's disease), or other disorders can become unable to move or speak despite being awake and alert. in this project, the investigators seek to further translate knowledge about interpreting brain signals related to movement, and to further develop an intracortical brain-computer interface (ibci) that could restore rapid and intuitive use of communication apps on tablet computers by people with paralysis.

the goal of this project is to advance the methods by which people with tetraplegia can gain intuitive, reliable control of communication apps on industry-standard tablet computers through use of an intracortical brain-computer interface (ibci).

Eligibility criteria:
inclusion criteria: * clinical diagnosis of spinal cord injury, brainstem stroke, muscular dystrophy, amyotrophic lateral sclerosis or other motor neuron disorders * complete or incomplete tetraplegia (quadriplegia) * must live within a three-hour drive of the study site * prior enrollment in braingate2 clinical trial (nct00912041) exclusion criteria: * visual impairment such that extended viewing of a computer monitor would be difficult even with ordinary corrective lenses * chronic oral or intravenous steroids or immunosuppressive therapy * other serious disease or disorder that could seriously affect ability to participate in the study (there are additional exclusion criteria)
vitamin a therapy for tuberculosis

Conditions: Pulmonary Tuberculosis; HIV Infections

Summary: the study will determine whether a daily vitamin and mineral supplement (a multivitamin including vitamin a) will improve health when added to standard chemotherapy for tuberculosis. this study will compare the effectiveness of the multivitamin in hiv infected and hiv uninfected patients.

by the year 2000, 13.8 % of individuals with hiv will be co-infected with tuberculosis (tb). despite effective tb chemotherapy, mortality rates remain extremely high, and no simple, inexpensive intervention is available. prior to the discovery of antibiotic treatment, cod-liver oil, a potent source of vitamin a, was the standard treatment for tb. vitamin a is essential for normal immune function, and vitamin a supplementation is used in many countries to reduce mortality in children. vitamin a deficiency in hiv infected people has been associated with increased mortality in the united states, haiti, malawi, and uganda. this study will determine whether daily vitamin a supplementation, given concurrently with tb chemotherapy, will reduce mortality in adults with hiv and tb. all study participants will receive standard tb chemotherapy (isoniazid, rifampicin, streptomycin, pyrazinamide) for the first 2 months, followed by isoniazid and ethambutol for the following 6 months. participants will be randomized to receive either a daily vitamin and mineral supplement or placebo. participants will be followed for 24 months after study enrollment.

Eligibility criteria:
inclusion criteria: * sputum-confirmed pulmonary tuberculosis * resident of zomba or blantyre districts, malawi * willing to take tuberculosis chemotherapy as recommended by the national tuberculosis control programme exclusion criteria: * prior treatment for tuberculosis

Keywords: vitamin a
efficacy of administration of ace-inhibition on autonomic and peripheral neuropathy in patients with diabetes mellitus

Conditions: Diabetic Autonomic Neuropathy

Summary: patients with diabetes mellitus and definite autonomic and peripheral neuropathy were randomized to receive quinapril or no treatment for 2 years.


Eligibility criteria:
inclusion criteria: * diabetes mellitus with both autonomic and peripheral neuropathy exclusion criteria: * hypertension, coronary heart disease
intensive statin therapy effect on post-operative atrial fibrillation (poaf)

Conditions: Cardiothoracic Surgery; Post-operative Atrial Fibrillation

Summary: this study will compare the effects of 20 mg of atorvastatin to 80 mg of atorvastatin for the prevention of atrial fibrillation after cardiothoracic surgery. the study hypothesis is that 80 mg of atorvastatin will be more effective at preventing atrial fibrillation compared to 20 mg.

this is a randomized, double-blind comparison of two doses of atorvastatin for prevention of post-operative atrial fibrillation.

Eligibility criteria:
inclusion criteria: * age 19 or older * undergoing elective cardiothoracic surgery exclusion criteria: * emergency cardiothoracic surgery * history of permanent atrial fibrillation * acute coronary syndrome within 7 days * antiarrhythmic drug use in the past 3 months * receiving maximal tolerated dose of statin therapy * receiving fibrate therapy * history of statin intolerance * significant liver impairment (aspartate aminotransferase/alanine aminotransferase(ast/alt)\>2x uln) * serum creatinine \> 3 mg/dl * pregnancy or breastfeeding

Keywords: post-operative atrial fibrillation poaf a-fib
nutritional counseling in systemic immunoglobulin light-chain amyloidosis

Conditions: Amyloidosis

Summary: poor nutritional status is common in patients with systemic immunoglobulin light-chain (al) amyloidosis and has been associated with mortality and impaired quality of life (qol). we investigated whether nutritional counseling is beneficial to the maintenance of nutritional status and qol in al outpatients.


Eligibility criteria:
inclusion criteria: * treatment naïve patients with with systemic immunoglobulin light-chain amyloidosis * availability to planned measurements and to written informed consent exclusion criteria: * age \< 18 years * indication to organ transplantation * indication to autologous stem cell transplantation * need to start or ongoing dialysis * ascites or massive edema * need to start or ongoing artificial nutrition
a phase i dose escalation study of oral sb939 administered alone or with azacitidine

Conditions: Solid Tumors; Hematologic Malignancies; Myelodysplastic Syndrome

Summary: this is an open label, dose escalation study with 3 arms (arms a, b, and c). arm a will assess the safety and tolerability of escalating doses of sb939 in cohorts of patients with advanced solid tumors. arm b will assess the safety and tolerability of escalating doses in cohorts of patients with advanced hematologic malignancies. arm c will assess the safety and tolerability of sb939 in combination with standard azacitidine therapy.


Eligibility criteria:
inclusion criteria: arms a \& b: * patients with solid tumors in arm a and hematologic malignancies in arm b that is classified as intermediate 1 or greater according to the international prognostic scoring system (ipss) risk category for whom therapy is indicated; * ecog performance status (ps) 0-2; * patients must have adequate non-hematologic organ system function. arm c: * patients with mds that is classified as intermediate 1 or greater according to the international prognostic scoring system (ipss) risk category for whom therapy is indicated; * have not been treated with azacitidine and are a candidate for treatment with azacitidine; * ecog performance status (ps) 0-2; * patients must have adequate non-hematologic organ system function.

Keywords: sb939 myelodysplastic syndrome combination with azacitidine solid malignancies hematologic malignancies hdac inhibitor refractory to standard therapy
quantification of radiological pulmonary involvement in acute respiratory failure

Conditions: SARS (Severe Acute Respiratory Syndrome)

Summary: acute respiratory failure (arf) is a common condition and a common reason for urgent medical consultation. assessing the extent of respiratory impairment is important to improve the management of patients with arf. when acute respiratory failure is caused by pathology of the pulmonary parenchyma, quantification of pulmonary radiographic involvement may be a component of the initial assessment of severity. this radiographic quantification would only be usable in clinical routine if it can be automated and provide a real-time result. the objective of this work is to assess the feasibility of an automated technique for quantifying radiological lung damage in situations of known or potential arf.


Eligibility criteria:
inclusion criteria: * patients over 18 years of age * presenting a situation at risk of acute respiratory failure * requiring thorax imaging when they were treated. exclusion criteria: * patients with anatomically incomplete thoracic imaging (e.g., technical acquisition error).

Keywords: sars severe acute respiratory syndrome automated quantification lung volume thorax imaging
continuous blood purification for regulation of early inflammatory response in severe acute pancreatitis

Conditions: Acute Pancreatitis

Summary: systemic inflammatory response syndrome(sirs) is common in patients with severe acute pancreatitis (sap) in early stage. continuous blood purification (cbp), especially continuous veno-venous hemofiltration(cvvh) is proved to have an important role in sap patients to control sirs. but the detail treatment for this is controversial. in this study, the investigators aim to evaluate the different effects of three kinds of treatment protocols which is cvvh 6h,continuous venovenous hemodiafiltration(cvvhdf) 6h,cvvh 10h for first three days in sap patients. compare the vital sign, sirs parameters, and others between these three groups. this study will try to find a better way for cbp in patients with sap

condition severe acute pancreatitis intervention cvvh 6 hours for first three days cvvh 10 hours for first three days cvvhdf 6 hours for first three days all therapeutic volume is 45ml/kg.h, device: braxter hf 1200

Eligibility criteria:
inclusion criteria: inclusion criteria: 1. diagnosis of pancreatitis: * typical pain * increase in serum lipase or amylase * onset of abdominal pain within \<=72h before admission 2. the diagnosis criteria of severe acute pancreatitis is according to atlanta criteria revisited in 2012 3. no chronic diseases such as chronic obstructive pulmonary disease, diabetes mellitus and so on 4. age from 18 to 65 years old besides criteria above, the patient should also satisfied one of these cbp criteria: 1. have acute kidney injury satisfied rifle classification (risk above): increased serum creatinine \> 1.5 times baseline，26.5umol/l increase, or urine output \< 0.5ml/kg.h for 6 hours 2. systemic inflammatory response syndrome: temperature \>38℃ or\ 12\*10\^9/l，or\< 4\*10\^9/l 3. refractory acid-base and electrocyte balance disorder, metabolic acidosis conservative treatment is not effective. exclusion criteria: 1. pregnancy 2. chronic pancreatitis 3. immunosuppression condition such as hiv, corticosteroid for 3 weeks in 60 days; white blood cell \< 0.5\*10\^9/l for 10 days

Keywords: systemic inflammatory response syndrome continuous blood purification
butylphthalide's safety and efficacy for improving neurological function prognosis in patients with cardiac arrest (bnca trial)

Conditions: Butylphthalide; Cardiac Arrest; Neuroprotective Drugs

Summary: butylphthalide (nbp) is a neuroprotective medication capable of ameliorating neurological dysfunction induced by ischemia, hypoxia, and reperfusion injury in the brain. however, evidence regarding the improvement of neurological function prognosis in patients with return of spontaneous circulation (rosc) after cardiac arrest (ca) by nbp is limited. this study aims to evaluate the safety and efficacy of nbp treatment in improving the neurological function prognosis of patients with rosc after ca.the study will be a single-center, randomized, double-blind, placebo-controlled trial. the sample size is estimated to be 100 patients. eligible patients will be randomly allocated in a 1:1 ratio to receive either nbp or placebo treatment daily for a duration of 14 days. the initial administration of nbp or placebo treatment will commence within 6 hours after rosc following ca. the primary outcome is the proportion of patients with cerebral performance category (cpc) scores of 1-2 at 90 days after randomization in each group. the primary safety outcome is the percentage of severe adverse events occurring during the 14-day treatment period. this trial will determine the efficacy of nbp in providing neuroprotective effects for patients with rosc after ca.


Eligibility criteria:
inclusion criteria: 1. age 18-80 years old. 2. gcs scores ≤8 upon admission. 3. rosc ≥30min. 4. signed the informed consent form. exclusion criteria: 1. cardiac arrest due to irreversible causes such as trauma, poisoning, etc. 2. cardiac arrest due to end-stage conditions such as advanced cancer. 3. persistent cardiogenic shock that is unreversed (defined as a systolic blood pressure persistently \<90mmhg despite treatment with fluid resuscitation, vasopressor agents, and inotropic medications). 4. presence of pre-existing cerebrovascular disease prior to cardiac arrest or confirmed intracranial hemorrhage by ct scan following admission. 5. pre-existing cpc scores of 3-5 prior to cardiac arrest. 6. prior use of nbp or any medication containing nbp before cardiac arrest. 7. presence of severe hepatic or renal dysfunction before cardiac arrest (defined as ≥3× upper limit of normal alanine transaminase or ≥2× upper limit of normal creatinine). 8. bradycardia or sick sinus syndrome occurs after rosc. 9. history of prior drug or food allergies, or known allergies to the medication components used in this study. 10. existence of treatment limitations (patient or their legal representative refusing advanced life support treatment, including mechanical ventilation, chest compressions, targeted temperature management, etc.). 11. presence of severe bleeding tendency upon admission. 12. body temperature \<30℃ upon admission. 13. pregnant or lactating women, or reproductive-age females with elevated serum hcg levels. 14. other conditions deemed unsuitable for this trial by the principal investigator.